Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome

Circulation

Volumn 110, Issue 4, 2004, Pages 419-425

  Vaziri, N D ^a,b   Liang, K H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ACAT inhibitor; Cholesterol; Hyperlipidemia; Nephrotic syndrome; Proteinuria

Indexed keywords

2,2 DIMETHYL N (2,4,6 TRIMETHOXYPHENYL)DODECANAMIDE; ACYL COENZYME A:CHOLESTEROL ACYLTRANSFERASE 2; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL RESPONSIVE PROTEIN; HIGH DENSITY LIPOPROTEIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID; LIPID REGULATORY FACTOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROTEIN; PUROMYCIN; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ACAT 2 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FOAM CELL; GENE; HYPERLIPIDEMIA; HYPOALBUMINEMIA; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALE; NEPHROTIC SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEINURIA; RAT; RAT STRAIN; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPIDEMIAS; HYPOALBUMINEMIA; LECITHIN ACYLTRANSFERASE DEFICIENCY; LIVER; MALE; NEPHROTIC SYNDROME; PROTEINURIA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LDL; RECEPTORS, SCAVENGER; RNA, MESSENGER; STEROL O-ACYLTRANSFERASE; TRIGLYCERIDES;

EID: 3342943329     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000136023.70841.0F     Document Type: Article

References (54)

1. Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int (Nephrology Forum). 2003;63:1964-1976.
2. Kaysen GA. Hyperlipidemia of the nephrotic syndrome. Kidney Int Suppl. 1991;31:58-515.
3. Joven J, Villabona C, Vilella E, et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med. 1990;323:579-584.
4. Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis. 1994;23: 331-346.
5. Ordonez JD, Hiatt RA, Killebrew EJ, et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44: 638-642.
6. Ruggenenti P, Remuzzi G. The role of protein traffic in the progression of renal diseases. Annu Rev Med. 2000;51:315-327.
7. Vaziri ND, Liang K. Downregulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int. 1996;50:887-893.
8. Vaziri ND, Sato T, Liang K. Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis. Kidney Int. 2003;63:1756-1763.
9. Warwick GL, Packard CJ, Demant T, et al. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int. 1991;40:129-138.
10. Warwick GL, Caslake MJ, Boulton-Jones JM, et al. Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism. 1990;39: 187-192.
11. Vaziri ND, Liang K, Park JS. Acquired lecithin:cholesterol acyltransferase (LCAT) deficiency in nephrotic syndrome. Am J Physiol. 2001; 49:F823-F829.
12. Moulin P, Appel GB, Ginsberg HN, et al. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J Lipid Res. 1992;33:1817-1822.
13. Liang K, Vaziri ND. Downregulation of hepatic high-density lipoprotein receptor, SR-B1 in nephrotic syndrome. Kidney Int. 1999;56:621-626.
14. Muls E, Rosseneu M, Daneels R, et al. Lipoprotein distribution and composition in the human nephrotic syndrome. Atherosclerosis. 1985;54: 225-237.
15. Kaysen GA, Hoye E, Jones H Jr. Apolipoprotein AI levels are increased in part as a consequence of reduced catabolism in nephrotic rats. Am J Physiol. 1995;268:F532-F540.
16. Sparks CE, Tennenberg SD, Marsh JB. Catabolism of the apolipoproteins of HDL in control and nephrotic rats. Biochim Biophys Acta. 1981; 665:8-12.
17. Vaziri ND, Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int. 1995;48: 1979-1985.
18. Liang KH, Oveisi F, Vaziri ND. Gene expression of hepatic cholesterol 7 alpha-hydroxylase in the course of puromycin-induced nephrosis. Kidney Int. 1996;49:855-860.
19. Sun X, Jones H Jr, Joles JA, et al. Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis. Am J Physiol. 1992;262:F755-F761.
20. De Sain-Van der Veiden MG, Reijingould DJ, Kaysen GA, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol. 1998;9:1474-1481.
21. Liang K, Vaziri ND. Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med. 1997;130:387-394.
22. Liang K, Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrotic syndrome. Kidney Int. 19997;51:1933-1937.
23. Sato T, Liang K, Vaziri ND. Downregulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int. 2002; 61:157-162.
24. Liang K, Vaziri ND. Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int. 1997;51:1933-1937.
25. Sato T, Liang K, Vaziri ND. Protein restriction and AST-RO improve lipoprotein lipase and VLDL receptor in focal glomerular sclerosis. Kidney Int. 2003;64:1780-1786.
26. Vaziri ND, Kim CH, Phan D, et al. Upregulation of acyl-CoA: diacylglycerol acyltransferase (DGAT) expression in nephrotic syndrome. Kidney Int. 2004;66:262-267.
27. Joles JA, Bijleveld C, van Tol A, et al. Plasma triglyceride levels are higher in nephrotic than in analbuminemic rats despite a similar increase in hepatic triglyceride secretion. Kidney Int. 1995;47:566-572.
28. Joles JA, Bijleveld C, van Toi A, et al. Estrogen replacement during hypoalbuminemia may enhance atherosclerotic risk. J Am Soc Nephrol. 1997;8:1870-1876.
29. 3H-palmitate. Lipids. 1980;15:108-112.
30. Shafrir E, Brenner T. Lipoprotein lipid and protein synthesis in experimental nephrosis and plasmapheresis, I: studies in rat in vivo. Lipids. 1979;14:695-702.
31. Vaziri ND, Liang KH. Upregulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int. 2002;61: 1769-1775.
32. Chang CC, Huh HY, Cadigan KM, et al. Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J Biol Chem. 1993;268: 20747-20755.
33. Anderson RA, Joyce C, Davis M, et al. Identification of a form of acyl-CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J Biol Chem. 1998;273:26747-26754.
34. Cases S, Novak S, Zheng YW, et al. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase: its cloning, expression, and characterization. J Biol Chem. 1998;273:26755-26764.
35. Oelkers P, Behari A. Cromley D, et al. Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes. J Biol Chem. 1998;273:26765-26771.
36. Carr TP, Hamilton RL Jr, Rudel LL. ACAT inhibitors decrease secretion of cholesteryl esters and apolipoprotein B by perfused livers of African green monkeys. J Lipid Res. 1995;36:25-36.
37. Cianflone KM, Yasruel Z, Rodriguez MA, et al. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res. 1990;31:2045-2055.
38. Huff MW, Telford DE, Barrett PH, et al. Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol-free diet. Arterioscler Thromb. 1994;14:1498-1508.
39. Bocan TM, Krause BR, Rosebury WS, et al. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 2000;20:70-79.
40. Chang CC, Doolittle GM, Chang TY. Cycloheximide sensitivity in regulation of acyl coenzyme A:cholesterol acyltransferase activity in Chinese hamster ovary cells, I: effect of exogenous sterols. Biochemistry. 1986;25:1693-1699.
41. Post SM, Zoeteweij JP, Bos MH, et al. Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat. Hepatology. 1999;30:491-500.
42. Lee HT, Sliskovic DR, Picard JA, et al. Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents: CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J Med Chem. 1996;39:5031-5034.
43. Liang K, Vaziri ND. HMG-CoA reductase, cholesterol 7α-hydroxylase, LCAT, ACAT, LDL receptor and SRB-1 in hereditary analbuminemia. Kidney Int. 2003;64:192-198.
44. Vaziri ND, Liang K, Parks JSL. Downregulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192-2196.
45. Liang K, Vaziri ND. Upregulation of acyl-CoA: cholesterol acyltransferase in chronic renal failure. Am J Physiol. 2002;283:E676-E681.
46. Klein RL, Rudel LL. Cholesterol absorption and transport in thoracic duct lymph lipoproteins of nonhuman primates: effect of dietary cholesterol level. J Lipid Res. 1983;24:343-356.
47. Genest J Jr, Marcil M, Denis M, et al. High density lipoproteins in health and in disease. J Invest Med. 1999;47:31-42.
48. Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271: 518-520.
49. Keane WF. Lipids and progressive renal failure. Wien Klin Wochenschr. 1996;108:420-424.
50. Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565-570.
51. Park YS, Guijarro C, Kim Y, et al. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis. 1998;31:190-194.
52. Chan PC, Robinson JD, Yeung WC, et al. Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol Dial Transplant. 1992;7:93-99.
53. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl. 1999;71:S2-S5.
54. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 2002;40:67-73.